Bio Green Med Solution, Inc (BGMS) Fair Value & Analysis
Healthcare · US · Market cap $4.2M
Bio Green Med Solution, Inc
BGMS · US
Fair value as of: Jul 14, 2026
From 1 valuation models · updated today
Share price +16.4% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.6000 – $17.15 · fair‑value band $0.5015 – $0.9435 · the $0.9076 price screens above the $0.7565 fair value. As of Jul 14, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Bio Green Med Solution, Inc (BGMS) currently trades at $0.9076, while our model-based Fair Value estimate is $0.7565 — implying the stock looks roughly 16.7% overvalued today. We read business quality at 37/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $1.5M. It earns a return on equity of 20.6%. The balance sheet holds a net cash position of $3.5M. The stock trades on a trailing P/E of 0.1. Fundamentals as of Jul 14, 2026
Our scenario range runs from $0.5015 (bear case) to $0.9435 (bull case); at $0.9076, the current price sits within that range. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside — at -17%, BGMS screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 14, 2026. TTM = trailing twelve months.
About the company
Bio Green Med Solution, Inc. engages in the distributing, trading, and installation of protective and fire safety materials and equipment, and fire protection and prevention systems. It is also involved in research and development of pharmaceuticals. The company was formerly known as Cyclacel Pharmaceuticals, Inc. and changed its name to Bio Green Med Solution, Inc. in September 2022. Bio Green Med Solution, Inc. was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bio Green Med Solution, Inc reported revenue of $747K in FY2025 versus $0 in FY2021. Reported net income was −$3.0M in FY2025.
Is BGMS fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 14, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.04 | R$46.95 | -10% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$27.80 | R$23.67 | -15% |
| Moderna, Inc M1RN34 | R$14.75 | R$4.91 | -67% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Bio Green Med Solution, Inc (BGMS) undervalued?
What is the fair value of BGMS?
What is the quality score of BGMS?
What is the revenue of Bio Green Med Solution, Inc (BGMS)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Bio Green Med Solution, Inc analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.